N4 Pharma is a specialist pharmaceutical company that aims to revolutionize drug delivery systems. They have developed a groundbreaking technology called Nuvec ®, which utilizes novel silica nanoparticles with a patented spiky structure. These nanoparticles are designed to load, protect, and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly, making them ideal for gene therapy, cancer therapeutics, and vaccines.

Established in 2014, N4 Pharma went public on the AIM stock market in May 2017. Currently in the pre-clinical phase, Nuvec ® is available for licensing to pharmaceutical and biotech partners for nucleic acid product development. This innovative technology addresses the limitations of existing delivery systems and offers a promising solution for the medical community.

N4 Pharma's focus is on advancing the field of pharmaceuticals by providing this unique delivery system and supporting further research and development. Their goal is to improve the efficacy and safety of drug delivery, ultimately benefiting patients and healthcare providers alike. Watch their video animation to learn more about Nuvec ® and its potential impact on the future of medicine